Boston, Massachusetts
March 4–7, 2018


Conference Dates and Location: 
February 23-26, 2015 | Seattle, Washington
Abstract Number: 

Impact of Deferring HCV Treatment on Liver-Related Events in HIV+ Patients


Cindy Zahnd1, Luisa P. Salazar-Vizcaya1, Jean-François Dufour2, Beat Müllhaupt3, Gilles Wandeler1, Roger Kouyos3, Barbara Bertisch1, Andri Rauch2, Olivia Keiser1
1 Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 2 University Hospital Bern , Bern, Switzerland. 3 University Hospital Zurich, Zurich, Switzerland.

Abstract Body: 

Background: Successful treatment of HCV infections substantially reduces the risk of liver-related complications. However, cost considerations and the availability of better treatment options in the future often leads to the deferral of treatment of HCV infection in patients with limited liver fibrosis. In this study, we modelled the impact of different treatment strategies on liver fibrosis progression among HIV-infected patients with incident HCV infection.

Methods: We developed an individual-based model of liver disease progression. We parameterized it with observed data on incident HCV infections among men who have sex with men from the Swiss HIV Cohort Study (SHCS) and with published data. We simulated patients from HCV infection through stages of liver disease: from fibrosis grade F0 to F4, decompensated cirrhosis, hepatocellular carcinoma and death. Liver disease progression was affected by age at HCV infection and alcohol consumption. Patients also progressed through the care cascade: they could be diagnosed, treated and succeed or fail treatment. We assumed treatment efficacy with Interferon (IFN)-free regimen was 90%. Successfully treated patients had a residual liver fibrosis progression of 0.1 times the rate of patients with detectable HCV. We compared liver-related events and duration of infectiousness (ie. detectable viral load) between the following strategies: treatment of all patients one month after diagnosis, one year after diagnosis or as they reach F2, F3 or F4.

Results: Delaying treatment until 1 year after diagnosis or until F2, F3 or F4 led to 14, 43, 142 and 418 additional cases of liver-related deaths per 1000 HCV infections as compared with treating all patients one month after diagnosis. The average time people were infectious increased from 5 years with early (one month after diagnosis) to 21 years with late (F4) treatment (Figure).

Conclusions: Our model suggests that timely treatment of HCV infection is important: Patients can progress to end-stage liver disease after HCV clearance if treatment is delayed until later stages of liver disease due to imperfect treatment responses and residual fibrosis progression in HIV-infected patients. Delaying treatment also increases the risk of HCV transmission: the average time during which patients are infectious is four times higher if patients are treated in F4 than if they are treated one month after diagnosis.

SHCS is our base scenario and is given here for reference, it depicts current practise in the SHCS.
HCC: Hepatocellular Carcinoma

Session Number: 
Session Title: 
Curing HCV: Mission Accomplished
Presenting Author: 
Zahnd, Cindy
Presenter Institution: 
Institute of Social and Preventive Medicine, University of Bern